BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2701308)

  • 1. Acute physical dependence in man: repeated naloxone-precipitated withdrawal after a single dose of methadone.
    Wright C; Bigelow GE; Stitzer ML
    NIDA Res Monogr; 1989; 95():395-6. PubMed ID: 2701308
    [No Abstract]   [Full Text] [Related]  

  • 2. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methadone detoxification: effects of methadone dose versus time in treatment.
    McCaul ME; Stitzer ML; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1984 Mar; 49():269-74. PubMed ID: 6434971
    [No Abstract]   [Full Text] [Related]  

  • 4. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of a Neuro-Stimulator Device vs. methadone in alleviating opiate withdrawal symptoms.
    Elmoghazy E; Johnson BD; Alling FA
    NIDA Res Monogr; 1989; 95():388-9. PubMed ID: 2701306
    [No Abstract]   [Full Text] [Related]  

  • 6. Outpatient comparison of buprenorphine and methadone maintenance. I. Effects on opiate use and self-reported adverse effects and withdrawal symptomatology.
    Johnson RE; Fudala PJ; Jaffe JH
    NIDA Res Monogr; 1990; 105():585-6. PubMed ID: 1876130
    [No Abstract]   [Full Text] [Related]  

  • 7. Use predicts treatment outcome, not opiate dependence or withdrawal.
    Kosten TA; Bianchi MS; Kosten TR
    NIDA Res Monogr; 1989; 95():459-60. PubMed ID: 2641030
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment.
    Trujols J; SiƱol N; de los Cobos JP
    J Clin Psychopharmacol; 2010 Feb; 30(1):95-6; author reply 96. PubMed ID: 20075667
    [No Abstract]   [Full Text] [Related]  

  • 10. Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans.
    Stitzer ML; Wright C; Bigelow GE; June HL; Felch LJ
    Drug Alcohol Depend; 1991 Dec; 29(1):39-46. PubMed ID: 1665778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical mismanagement in public methadone programs.
    Blansfield HN
    Conn Med; 1994 Mar; 58(3):161-4. PubMed ID: 8039380
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute opioid physical dependence in humans: maximum morphine-naloxone interval.
    Kirby KC; Stitzer ML; Heishman SJ
    NIDA Res Monogr; 1989; 95():393-4. PubMed ID: 2641007
    [No Abstract]   [Full Text] [Related]  

  • 14. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methadone withdrawal psychosis.
    Levinson I; Galynker II; Rosenthal RN
    J Clin Psychiatry; 1995 Feb; 56(2):73-6. PubMed ID: 7852256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of methadone.
    Layson-Wolf C; Goode JV; Small RE
    J Pain Palliat Care Pharmacother; 2002; 16(1):29-59. PubMed ID: 14650449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the withdrawal responses of heroin and methadone addicts during detoxification.
    Gossop M; Strang J
    Br J Psychiatry; 1991 May; 158():697-9. PubMed ID: 1860023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosis after ultrarapid opiate detoxification.
    Shreeram SS; McDonald T; Dennison S
    Am J Psychiatry; 2001 Jun; 158(6):970. PubMed ID: 11384923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.